0521779407-10 CUNY1086/Karliner 0 521 77940 7 June 7, 2007 18:40
832 Infective Endocarditis
■HACEK organisms treated with ceftriaxone for 4 weeks (6 weeks for
prosthetic valves); therapy in the allergic patient not established, but
trimethoprim-sulfamethoxazole, fluoroquinolones and aztreonam
have in vitro activity
follow-up
■Blood cultures usually negative in 3–5 days; fever may persist 10–
12 days; persistent fever should prompt evaluation for myocardial
abscess, infected or sterile systemic emboli with or without infarc-
tion, superinfection or drug reaction
■Most relapses occur within 1–2 months of completion of therapy;
careful clinical follow-up and blood cultures every other week to
detect early relapses
■Progressive valvular dysfunction after successful antibiotic therapy
may require valve replacement, especially in the first year.
complications and prognosis
■Major complications include valvular destruction with heart fail-
ure requiring valve replacement, myocardial abscess, systemic
embolization with infarction (kidney, spleen), mycotic aneurysms
that can rupture (great vessels or intracerebral vessels) and pul-
monary emboli resulting in infarcts or abscesses.
■Use of prophylactic antibiotics indicated in high-risk patients (pros-
thetic valves, previous endocarditis) or moderate-risk patients (con-
genital abnormalities other than atrial septal defects, rheumatic
heart disease with valvular dysfunction, mitral valve prolapse with
regurgitation) undergoing procedures likely to result in bacteremia
(dental procedures associated with significant bleeding, periodon-
tal procedures, implant placement; respiratory procedures that
breach the mucosa such as tonsillectomy; invasive gastrointestinal
procedures such as ERCP, sclerotherapy; invasive genitourinary pro-
cedures, prostatic surgery); for dental, respiratory or esophageal pro-
cedures, amoxicillin (clindamycin if penicillin allergic) 1 hour before;
for gastrointestinal procedures (other than esophageal) and geni-
tourinary procedures in high-risk patients ampicillin plus gentam-
icin parenterally 30 minutes before and either ampicillin g IV or IM
or amoxicillin orally, 6 hours after (vancomycin instead of ampicillin
in the penicillin-allergic patient); in moderate-risk patients amoxi-
cillin 1 hour before (vancomycin as above for the penicillin-allergic
patient)